在庫拠点

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 在庫状況によります

Documentation

MSDSをダウンロード

サンプルCOAをダウンロード

内容: HPLC、MASS/LC-MS、1H NMR、FT-IR、含量、構造解析レポート（SER）、および製品に応じた追加分析データ。

3-Deoxy 3-Chloro Abiraterone

● Under Development

カタログ番号:	VL830022
CAS番号:	N/A
分子式:	C24H30ClN
分子量:	367.95 g/mol

ご用件は何ですか?

RFQリストに追加

に関する追加情報 3-Deoxy 3-Chloro Abiraterone

親薬物

Abiraterone

IUPAC名

1-((8R, 9S, 10R, 13S, 14S)-10, 13-Dimethyl-17-(pyridin-3-yl)-2, 7, 8, 9, 10, 11, 12, 13, 14, 15-decahydro-1H-cyclopenta[a]phenanthren-3-yl)ethan-1-one

薬局方同義語

N/A

Other Synonyms

N/A

SMILES

C[C@@]12C(C3=CC=CN=C3)=CC[C@@]1([H])[C@]4([H])CC=C5CC(Cl)CC[C@]5(C)[C@@]4([H])CC2

InChI

InChI=1S/C24H30ClN/c1-23-11-9-18(25)14-17(23)5-6-19-21-8-7-20(16-4-3-13-26-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22H,6,8-12,14H2,1-2H3/t18?,19-,21-,22-,23-,24+/m0/s1

説明

The compound 3-Deoxy 3-Chloro Abiraterone is a thoroughly characterized reference standard that complies with rigorous regulatory guidelines, including those from USP, EMA, JP, and BP. It is ideal for critical applications such as analytical method development, method validation (AMV), and quality control (QC), especially in the production of Abiraterone. Designed to support both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA), this product delivers the precision required for reliable results. Additionally, it includes a detailed Structure Elucidation Report (SER), ensuring accuracy and dependability for advanced analytical purposes. 3-Deoxy 3-Chloro Abiraterone or 1-((8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl)ethan-1-one, it is poorly absorbed and is susceptible to hydrolysis by esterases and is an orally active inhibitor of the steroidal enzyme CYP17A1 that is used in the treatment of prostate cancer.

References

Goldberg, Tamara, and Evangelina Berrios-Colon. â€œAbiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer.â€ Pharmacy and Therapeutics, vol. 38, no. 1, 1 Jan. 2013, pp. 23â€“26, www.ncbi.nlm.nih.gov/pmc/articles/PMC3628169/.